Skip to content

siddha medicine for PITHA PANDU[Anaemia]

The efficacy of the SIDDHA MANDOORAM [internal] in the treatment of PITHA PANDU [Iron Defeciency Anaemia]

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2011/06/001835
Enrollment
40
Registered
2011-06-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- PITHA PANDU [Iron Defeciency Anaemia]

Interventions

Intervention1: SIDDHA MANDOORAM: Kazharchi alavu [2gms],before food,twice a day with buttermilk for 48 days continously Intervention2: Siddha mandooram: constituents:Mandooram(Ferroso ferric oxide),Ka

Sponsors

National Institute of Siddha Tambaram SanatoriumDepartment of AYUSH Chennai Tamil Nadu
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patient willing to undergo blood investigation; Clinical symptoms of: Pallor Breathlessness Palpitation Anorexia Giddiness Lassitude Fatigue Koilonychias etc; Hemoglobin level less than normal range ie.,7-13 mg/dl for men,7-10mg/dl for women[Normal range:Male:14-18gms/dl;Female:11-15gms/dl]Patient blood smear showing Microcytic Hypochromic RBC; Patient willing to sign the informed consent stating that he/she will conscientiously stick to the treatment during 48 days but can be opt out of the trial of his/her own conscious discretion

Exclusion criteria

Exclusion criteria: Parasitic infection;Bleeding disorder[Bleeding piles,Menorrhagia];Pregnancy and lactation;Presence of any associated severe systemic illness[e.g RA,CA];Endocrine disorder[thyroid abnormality,Diabetes mellitus];cardiac disease;Renal disease; H/o of steriod exposure for prolonged time;Peptic ulcer;Gasterctomy;Inherited defects[sickle cell anaemia,Thalassemia];Malabsorption syndrome;Patient not willing to give blood sample.

Design outcomes

Primary

MeasureTime frame
Hemoglobin levelTimepoint: 49th day

Secondary

MeasureTime frame
1)Reduction in clinical symptoms 2)Changes in complete blood count 3)Changes in Iron supply studiesTimepoint: Before and After the treatment

Countries

India

Contacts

Public ContactDrNalini Sofia
dr.kmvm@gmail.com044-22411611

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026